Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice

Iyo Takemura-Uchiyama, Jumpei Uchiyama, Makoto Osanai, Norihito Morimoto, Tadashi Asagiri, Takako Ujihara, Masanori Daibata, Tetsuro Sugiura, Shigenobu Matsuzaki

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)

Abstract

Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacteremia invitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia.

Original languageEnglish
Pages (from-to)512-517
Number of pages6
JournalMicrobes and Infection
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 2014
Externally publishedYes

Keywords

  • Bacteriophage
  • Mouse
  • Podoviridae
  • Therapeutic
  • Therapy

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice'. Together they form a unique fingerprint.

Cite this